Ordookhani Arash, Burman Kenneth D
Endocrine Section, Department of Internal Medicine, Providence Hospital, Washington, DC, 20017.
Endocrine Section, MedStar Washington Hospital Center, Washington, DC, 20010.
Int J Endocrinol Metab. 2017 Mar 9;15(2):e42649. doi: 10.5812/ijem.42649. eCollection 2017 Apr.
There are contradictory results on the effect of hypothyroidism on the changes in hemostasis. Inadequate population-based studies limited their clinical implications, mainly on the risk of venous thromboembolism (VTE). This paper reviews the studies on laboratory and population-based findings regarding hemostatic changes and risk of VTE in hypothyroidism and autoimmune thyroid disorders.
A comprehensive literature search was conducted employing MEDLINE database. The following words were used for the search: Hypothyroidism; thyroiditis, autoimmune; blood coagulation factors; blood coagulation tests; hemostasis, blood coagulation disorders; thyroid hormones; myxedema; venous thromboembolism; fibrinolysis, receptors thyroid hormone. The papers that were related to hypothyroidism and autoimmune thyroid disorder and hemostasis are used in this review.
Overt hypothyroidism is more associated with a hypocoagulable state. Decreased platelet count, aggregation and agglutination, von Willebrand factor antigen and activity, several coagulation factors such as factor VIII, IX, XI, VII, and plasminogen activator-1 are detected in overt hypothyrodism. Increased fibrinogen has been detected in subclinical hypothyroidism and autoimmune thyroid disease rendering a tendency towards a hypercoagulability state. Increased factor VII and its activity, and plasminogen activator inhibitor-1 are among several findings contributing to a prothrombotic state in subclinical hypothyroidism.
Overt hypothyroidism is associated with a hypocoagulable state and subclinical hypothyroidism and autoimmune thyroid disorders may induce a prothrombotic state. However, there are contradictory findings for the abovementioned thyroid disorders. Prospective studies on the risk of VTE in various levels of hypofunctioning of the thyroid and autoimmune thyroid disorders are warranted.
关于甲状腺功能减退对止血变化的影响存在相互矛盾的结果。基于人群的研究不足限制了它们的临床意义,主要是关于静脉血栓栓塞(VTE)的风险。本文综述了关于甲状腺功能减退和自身免疫性甲状腺疾病中止血变化及VTE风险的实验室和基于人群的研究结果。
使用MEDLINE数据库进行了全面的文献检索。检索词如下:甲状腺功能减退;自身免疫性甲状腺炎;血液凝固因子;血液凝固试验;止血、血液凝固障碍;甲状腺激素;黏液性水肿;静脉血栓栓塞;纤维蛋白溶解、甲状腺激素受体。本综述使用了与甲状腺功能减退、自身免疫性甲状腺疾病和止血相关的论文。
显性甲状腺功能减退更常与低凝状态相关。在显性甲状腺功能减退中检测到血小板计数、聚集和凝集减少,血管性血友病因子抗原和活性降低,以及几种凝血因子如因子VIII、IX、XI、VII和纤溶酶原激活物-1减少。在亚临床甲状腺功能减退和自身免疫性甲状腺疾病中检测到纤维蛋白原增加,呈现出高凝状态的倾向。因子VII及其活性增加以及纤溶酶原激活物抑制剂-1是导致亚临床甲状腺功能减退血栓前状态的几个发现之一。
显性甲状腺功能减退与低凝状态相关,亚临床甲状腺功能减退和自身免疫性甲状腺疾病可能诱导血栓前状态。然而,上述甲状腺疾病存在相互矛盾的发现。有必要对不同程度甲状腺功能减退和自身免疫性甲状腺疾病中VTE的风险进行前瞻性研究。